Protalix BioTherapeutics, Inc.			
Form 8-K January 31, 2018			
UNITED STATES			
SECURITIES AND EXCHANGE COMMISSION			
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 15(d) of			
the Securities Exchange Act of 1934			
Date of Report (Date of Earliest Event Reported): January 31, 2018			
Protalix BioTherapeutics, Inc.			
(Exact name of registrant as specified in its charter)			

Delaware (State or other jurisdiction	001-33357	65-0643773 (IRS Employer	
(Commission File Number)			
of incorporation)	((00,000,000,000,000,000,000,000,000,00	Identification No.)	
2 Snunit Street Science Park, POB 455 Carmiel, Israel (Address of principal execu	20100 utive offices) (Zip Code)		
Registrant's telephone number, including area code +972-4-988-9488			
(Former name or former address, if changed since last report.)			
	——————————————————————————————————————	intended to simultaneously satisfy the filing obligation of general Instruction A.2. below):	
" Written co	ommunication pursuant to Rul	e 425 under the Securities Act (17 CFR 230.425)	
" Soliciting r	material pursuant to Rule 14a-	12 under the Exchange Act (17 CFR 240.14a-12)	
" Pre-commencement com	munication pursuant to Rule 1	4d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
" Pre-commencement com	nmunication pursuant to Rule	13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
•	e e	ing growth company as defined in Rule 405 of the Securities rities Exchange Act of 1934 (17 CFR §240.12b-2).	
Emerging growth company			

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Item 8.01. Other Events

On January 31, 2018, the Company issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company's plant cell-expressed recombinant, pegylated, cross-linked -galactosidase-A candidate for the treatment of Fabry disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Financial Statements and Exhibits

Item 9.01.

Exhibits

(d)

99.1 Press release dated January 31, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 31, 2018 **PROTALIX BIOTHERAPEUTICS, INC.**

By: /s/ Moshe Manor Name: Moshe Manor Title: President and

Chief Executive Officer